Schizophrenia and substance use comorbidity: a genome-wide perspective

Dual diagnosis with substance use disorders (SUDs) consistently contributes to the premature mortality and increased disability observed in schizophrenia. Large genome-wide association studies are providing the information needed to investigate the genetic architecture of psychiatric disorders. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Polimanti, Renato, Agrawal, Arpana, Gelernter, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359801/
https://www.ncbi.nlm.nih.gov/pubmed/28327175
http://dx.doi.org/10.1186/s13073-017-0423-3
_version_ 1782516451147513856
author Polimanti, Renato
Agrawal, Arpana
Gelernter, Joel
author_facet Polimanti, Renato
Agrawal, Arpana
Gelernter, Joel
author_sort Polimanti, Renato
collection PubMed
description Dual diagnosis with substance use disorders (SUDs) consistently contributes to the premature mortality and increased disability observed in schizophrenia. Large genome-wide association studies are providing the information needed to investigate the genetic architecture of psychiatric disorders. Here, we discuss recent genetic investigations of dual diagnosis (i.e., schizophrenia plus a SUD) and how these findings can inform public health messages.
format Online
Article
Text
id pubmed-5359801
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53598012017-03-22 Schizophrenia and substance use comorbidity: a genome-wide perspective Polimanti, Renato Agrawal, Arpana Gelernter, Joel Genome Med Comment Dual diagnosis with substance use disorders (SUDs) consistently contributes to the premature mortality and increased disability observed in schizophrenia. Large genome-wide association studies are providing the information needed to investigate the genetic architecture of psychiatric disorders. Here, we discuss recent genetic investigations of dual diagnosis (i.e., schizophrenia plus a SUD) and how these findings can inform public health messages. BioMed Central 2017-03-21 /pmc/articles/PMC5359801/ /pubmed/28327175 http://dx.doi.org/10.1186/s13073-017-0423-3 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Comment
Polimanti, Renato
Agrawal, Arpana
Gelernter, Joel
Schizophrenia and substance use comorbidity: a genome-wide perspective
title Schizophrenia and substance use comorbidity: a genome-wide perspective
title_full Schizophrenia and substance use comorbidity: a genome-wide perspective
title_fullStr Schizophrenia and substance use comorbidity: a genome-wide perspective
title_full_unstemmed Schizophrenia and substance use comorbidity: a genome-wide perspective
title_short Schizophrenia and substance use comorbidity: a genome-wide perspective
title_sort schizophrenia and substance use comorbidity: a genome-wide perspective
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359801/
https://www.ncbi.nlm.nih.gov/pubmed/28327175
http://dx.doi.org/10.1186/s13073-017-0423-3
work_keys_str_mv AT polimantirenato schizophreniaandsubstanceusecomorbidityagenomewideperspective
AT agrawalarpana schizophreniaandsubstanceusecomorbidityagenomewideperspective
AT gelernterjoel schizophreniaandsubstanceusecomorbidityagenomewideperspective

Ejemplares similares